Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

ESMO: New Analysis Reinforces Survival Benefits of Targeted Therapy for Advanced Pancreatic Cancer

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

October 23, 2026


October 26 2026

October 25 2026

October 24 2026

October 23 2026

October 22 2026

October 21 2026

October 20 2026

October 19 2026

October 18 2026

October 17 2026

October 16 2026

October 15 2026

October 14 2026

October 13 2026

October 12 2026